Potent in Vitro and In Vivo Efficacy of BYON4413, a Duba-Based Antibody-Drug Conjugate Targeting CD123 in Acute Myeloid Leukemia

被引：3
|
作者：
van der Lee, Miranda [1 ]
van Achtenberg, Tanja [1 ]
Brouwers-Vos, Annet [2 ]
van der Vleuten, Monique [1 ]
Kappers, Wendy [1 ]
Verheijden, Gijs [1 ]
Huls, Geert A. [3 ]
van Wigcheren, Glenn [1 ]
Ubink, Ruud [1 ]
Sesink, Aloys [1 ]
MacInnes, Alyson [1 ]
Schuringa, Jan Jacob [4 ]
Dokter, Wim [1 ]
机构：
[1] Byondis BV, Nijmegen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[3] Univ Med Ctr Groningen, Groningen, Netherlands
[4] Univ Med Ctr Groningen, Dept Expt Hematol, Groningen, Netherlands
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-177622
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia
    Boyiadzis, Michael
    Desai, Pinkal
    Daskalakis, Nikki
    Donnellan, William
    Ferrante, Lucille
    Goldberg, Jenna D.
    Grunwald, Michael R.
    Guttke, Christina
    Li, Xiang
    Perez-Simon, Jose Antonio
    Salamero, Olga
    Tucker, Trevor
    Xu, Xiaoying
    Yang, Jay
    Pemmaraju, Naveen
    Alonso-Dominguez, Juan Manuel
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (03): : 429 - 435
  • [22] A CD123-Targeting Antibody-Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow Cells
    Kovtun, Yelena
    Jones, Gregory
    Audette, Charlene
    Harvey, Lauren
    Gerard, Baudouin
    Wilhelm, Alan
    Bai, Chen
    Adams, Sharlene
    Goldmacher, Victor S.
    Chari, Ravi
    Chittenden, Thomas
    BLOOD, 2016, 128 (22)
  • [23] A Phase 1b/2 Study of IMGN632, a CD123-Targeting Antibody-Drug Conjugate (ADC), As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia
    Daver, Naval
    Sweet, Kendra L.
    Montesinos, Pau
    Wang, Eunice S.
    Aribi, Ahmed
    DeAngelo, Daniel J.
    Erba, Harry P.
    Martinelli, Giovanni
    Walter, Roland P.
    Altman, Jessica K.
    Advani, Anjali S.
    Curti, Antonio
    Sloss, Callum M.
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    BLOOD, 2020, 136
  • [24] Selection and Characterization of Antibody Clones Are Critical for Accurate Flow Cytometry-Based Monitoring of CD123 in Acute Myeloid Leukemia
    Cruz, Nicole M.
    Lam, Linda
    Sugita, Mayumi
    Galetto, Roman
    Gouble, Agnes
    Smith, Julianne
    Roboz, Gail J.
    Guzman, Monica L.
    BLOOD, 2016, 128 (22)
  • [25] Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia
    Cruz, Nicole M.
    Sugita, Mayumi
    Ewing-Crystal, Nathan
    Lam, Linda
    Galetto, Roman
    Gouble, Agnes
    Smith, Julianne
    Hassane, Duane C.
    Roboz, Gail J.
    Guzman, Monica L.
    LEUKEMIA & LYMPHOMA, 2018, 59 (04) : 978 - 982
  • [26] In vitro and in vivo activity of a highly potent and novel FGFR2/FGFR4 dual targeting antibody-drug conjugate
    Meyer, Matthew J.
    Jenkins, David
    Batt, David
    Mosher, Rebecca
    Isaacs, Randi
    Hu, Tiancen
    Capka, Vladimir
    Zhang, Xiamei
    Chen, Dongshu
    Tang, Lujia
    Daley, Mike
    Nowakowski, Patrycja
    Shim, Yeonju
    Jiang, Wei
    Ettenberg, Seth
    Lees, Emma
    CANCER RESEARCH, 2015, 75
  • [27] Targeting myeloid epithelial tyrosine kinase (MERTK) receptor in acute myeloid leukemia using a novel antibody-drug conjugate, RGX-019-MMAE
    Tyagi, Anudishi
    Siddiqui, Maryam
    Kurth, Isabel
    Takeda, Shugaku
    Eckstrom, Amanda
    Borgman, Jenny
    Maiti, Abhishek
    Battula, Venkata Lokesh
    CANCER RESEARCH, 2024, 84 (06)
  • [28] Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
    Goldberg, Aaron D.
    Atallah, Ehab
    Rizzieri, David
    Walter, Roland B.
    Chung, Ki-Young
    Spira, Alexander
    Stock, Wendy
    Tallman, Martin S.
    Cruz, Hans G.
    Boni, Joseph
    Havenith, Karin E. G.
    Chao, Grace
    Feingold, Jay M.
    Wuerthner, Jens
    Solh, Melhem
    LEUKEMIA RESEARCH, 2020, 95
  • [29] Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
    Daver, Naval G.
    Montesinos, Pau
    Deangelo, Daniel J.
    Wang, Eunice S.
    Papadantonakis, Nikolaos
    Todisco, Elisabetta
    Sweet, Kendra L.
    Pemmaraju, Naveen
    Lane, Andrew A.
    Torres-Minana, Laura
    Thompson, James E.
    Konopleva, Marina Y.
    Sloss, Callum M.
    Watkins, Krystal
    Bedse, Gaurav
    Du, Yining
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    Kantarjian, Hagop M.
    LANCET ONCOLOGY, 2024, 25 (03): : 388 - 399
  • [30] IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models
    Adams, Sharlene
    Wilhelm, Alan
    Harvey, Lauren
    Bai, Chen
    Yoder, Nicholas
    Kovtun, Yelena
    Chittenden, Thomas
    Pinkas, Jan
    BLOOD, 2016, 128 (22)
12345